Atopic Dermatitis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2034

The Atopic Dermatitis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, Abbvie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others

[Nevada, United States] - DelveInsight's "Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Atopic Dermatitis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Atopic Dermatitis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Atopic Dermatitis Market Report:
• The Atopic Dermatitis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
• In October, 2024: Incyte Corporation announced a Phase 3b, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
• In October, 2024: Amgen announced a Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
• In October, 2024: Pfizer announced a randomized, open-label, parallel-group study to evaluate the safety and efficacy of abrocitinib 100 mg and 200 mg tablets in participants aged 12 years and older with moderate to severe atopic dermatitis in india
• In October, 2024: Eli Lilly and Company announced that a Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis
• In October, 2024: AbbVie announced a Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
• In 2023, the total Atopic Dermatitis Market Size in 7MM was around USD 17 billion, which is expected to increase by 2034 during the study period (2020-2034) in the 7MM.
• 40% of the Atopic Dermatitis prevalent population is ≤ 18 years of age; ~60%of this population has an early onset i.e. at the age of 0-2 years.
• Diagnosis of atopic dermatitis remains of key importance. ~25% remain either undiagnosed or misdiagnosed. Also, a significant delay in diagnosis had been associated with the disease
• Key Atopic Dermatitis Companies are as follows: Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, Abbvie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma and others..
• Key Atopic Dermatitis Therapies are as follow: RINVOQ (upadacitinib), DUPIXENT (dupilumab), Rocatinlimab (KHK4083/AMG 451), VTAMA (tapinarof; JTE-061), Roflumilast, Etrasimod, Difelikefalin, Orismilast, APG777, ATI-2138, ADX-914, Rocatinlimab, Upadacitinib, CM310, Lebrikizumab
• Launching multiple stage Atopic Dermatitis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Atopic Dermatitis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atopic Dermatitis Overview:
Atopic dermatitis (AD), commonly known as eczema, is a chronic, inflammatory skin condition characterized by itchy, red, swollen, and cracked skin. It affects both children and adults, although it is more prevalent in pediatric populations. Atopic dermatitis is considered part of the "atopic triad" that includes asthma and allergic rhinitis, indicating its strong association with immune dysregulation.

Atopic Dermatitis Epidemiology Segmentation:
The Atopic Dermatitis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Atopic Dermatitis Total Prevalent Case
• Atopic Dermatitis Total Diagnosed Cases
• Atopic Dermatitis Total Diagnosed Cases by Gender
• Atopic Dermatitis Total Diagnosed Cases by Age

For more information about Atopic Dermatitis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atopic Dermatitis Market Insights
The atopic dermatitis market is experiencing robust growth due to the introduction of new therapies, particularly biologics. As of 2023, the global atopic dermatitis market was valued at USD 7 billion and is expected to grow at a CAGR of 12-14% through 2030, driven by the increasing prevalence of the condition and the rise in innovative treatment options.
Atopic Dermatitis Drugs Uptake
• Corticosteroids: Topical corticosteroids remain the first-line treatment for managing mild-to-moderate AD. However, long-term use is limited due to side effects such as skin thinning.
• Calcineurin Inhibitors: Tacrolimus (Protopic) and Pimecrolimus (Elidel) are widely used as second-line treatments, particularly in sensitive areas like the face.
• Topical PDE4 Inhibitors: Crisaborole (Eucrisa) is a non-steroidal topical treatment that has gained uptake for managing mild-to-moderate AD without the side effects associated with steroids.
• Dupilumab (Dupixent): Dupilumab, an IL-4 and IL-13 inhibitor, is the first biologic therapy approved for moderate-to-severe atopic dermatitis.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atopic Dermatitis Therapies and Key Companies:
• RINVOQ (upadacitinib): AbbVie
• DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals
• Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin
• VTAMA (tapinarof; JTE-061): Dermavant Sciences/Japan Tobacco Pharmaceutical/Torii Pharmaceutical
• Roflumilast: Arcutis Biotherapeutics
• Etrasimod: Pfizer
• Difelikefalin: Cara Therapeutics
• Orismilast: UNION therapeutics
• APG777: Apogee Therapeutics, Inc.
• ATI-2138: Aclaris Therapeutics, Inc.
• ADX-914: Q32 Bio Inc.
• Rocatinlimab: Amgen
• Upadacitinib: AbbVie
• CM310: Keymed Biosciences Co.Ltd
• Lebrikizumab: Eli Lilly and Company

Atopic Dermatitis Epidemiology:
Atopic dermatitis is one of the most common skin conditions globally, and its prevalence has been increasing, especially in industrialized countries. Key epidemiological insights include:
• It is estimated that 15-30% of children and 2-10% of adults worldwide are affected by atopic dermatitis.
• AD is more common in children, with about 60% of cases developing in the first year of life. By the age of 5, 85% of children with AD have experienced symptoms. However, the condition often persists into adulthood in 10-30% of patients.
• The prevalence of AD is higher in developed nations, particularly in North America, Europe, and parts of Asia. In countries like the United States and Western Europe, the prevalence of AD in children is estimated to be as high as 20-25%. On the other hand,

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Atopic Dermatitis Market Drivers:
• Rising Prevalence
• Innovation in Treatment
• Expansion into Pediatric Populations
• Improved Diagnosis and Awareness

Atopic Dermatitis Market Barriers:
• High Cost of Biologic Therapies
• Competition from Generics
• Patient Compliance

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Atopic Dermatitis Market Report:
• Study Period: 2020-2034
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Atopic Dermatitis Companies: Bausch Health Companies Inc., GlaxoSmithKline PLC, Nestle SA, Pfizer Inc., Regeneron Pharmaceuticals Inc., Evelo Biosciences, Abbvie Inc., Allergan PLC, Cara Therapeutics, Bristol-Myers Squibb Company, Sanofi S.A., LEO Pharma, and others
• Key Atopic Dermatitis Therapies: RINVOQ (upadacitinib), DUPIXENT (dupilumab), Rocatinlimab (KHK4083/AMG 451), VTAMA (tapinarof; JTE-061), Roflumilast, Etrasimod, Difelikefalin, Orismilast, APG777, ATI-2138, ADX-914, Rocatinlimab, Upadacitinib, CM310, Lebrikizumab
• Atopic Dermatitis Therapeutic Assessment: Current marketed and emerging therapies
• Atopic Dermatitis Market Dynamics: Atopic Dermatitis Market drivers and Atopic Dermatitis barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Atopic Dermatitis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Atopic Dermatitis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/atopic-dermatitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Atopic Dermatitis Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Disease Background and Overview
7. Epidemiology and Patient Population
8. Patient Journey
9. Key Endpoints in atopic dermatitis Clinical Trials
10. Marketed Therapies
11. Emerging Therapies
12. Atopic Dermatitis: The 7MM Analysis
13. Market Access and Reimbursement
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.